Question 1

What is combined oxidative phosphorylation defect type 9?

Accepted Answer

Combined oxidative phosphorylation defect type 9 is a mitochondrial disorder that impairs energy production due to a defect in mitochondrial protein synthesis. The condition is caused by pathogenic variants in the MRPL3 gene, which plays a critical role in the assembly of mitochondrial ribosomes. Affected individuals usually show an initially normal period of development that later gives way to a constellation of metabolic and multi-system issues in infancy. As the condition is very rare, it is understood to affect fewer than 1 in 1,000,000 people.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 9?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation defect type 9 begins with a period of typical early growth, followed by the onset of significant challenges. Affected infants often exhibit failure to thrive, poor feeding, and global developmental delay, with laboratory findings including an elevated lactate to pyruvate ratio, ketoacidosis, and metabolic acidosis. In addition, most individuals present with multi-system involvement such as hypertrophic cardiomyopathy, hepatomegaly, and abnormalities in liver enzymes. Not all individuals experience every feature, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 9?

Accepted Answer

Combined oxidative phosphorylation defect type 9 is caused by changes in the MRPL3 gene, which encodes a mitochondrial ribosomal protein essential for proper protein synthesis within the mitochondria. Disruption in the function of this protein leads to decreased activity in several mitochondrial respiratory chain complexes, thereby impairing the cell’s energy production. The condition is inherited in an autosomal recessive pattern, meaning that an affected child has inherited two copies of the altered gene, one from each parent. It is more commonly observed in families where parents share a common ancestor, as the probability of both carrying the same rare pathogenic variant increases. Associated genes include MRPL3.

Question 4

How is combined oxidative phosphorylation defect type 9 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 9 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 9?

Accepted Answer

combined oxidative phosphorylation defect type 9 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 9 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation defect type 9 is confirmed through molecular genetic testing that identifies pathogenic variants in MRPL3. In addition to genetic testing, clinicians evaluate the patient’s clinical history, developmental milestones, and a range of laboratory findings such as elevated lactate, abnormal liver enzymes, and metabolic acidosis. Because many of these features can be seen in other metabolic disorders, genetic confirmation is essential to distinguish this condition from other similar presentations.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 9?

Accepted Answer

Currently, management focuses on supportive care and symptom relief, as there are no specific foundational or approved treatments for combined oxidative phosphorylation defect type 9. Treatment is tailored to the individual's needs and typically involves a multidisciplinary team to address the nutritional, cardiac, hepatic, and metabolic complications that arise over time. Regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Genetic counseling is recommended for families to understand the inheritance and to guide family planning, and patients should discuss management options with their healthcare team.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 9?

Accepted Answer

Complications from combined oxidative phosphorylation defect type 9 can include issues with growth and development, as many affected children experience failure to thrive and developmental delays. Additionally, multi-system involvement may lead to problems such as hypertrophic cardiomyopathy, liver enlargement, and metabolic disturbances. Regular monitoring is important to catch these complications early and manage them effectively.

Question 9

How does combined oxidative phosphorylation defect type 9 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation defect type 9 can be challenging for both patients and their families. Daily life may involve managing feeding difficulties, regular medical appointments, and therapies to support development. Families often need to work closely with a healthcare team to address the various symptoms and complications that can arise, ensuring that their loved one receives the best care possible.

Question 10

What is the long-term outlook for someone with combined oxidative phosphorylation defect type 9?

Accepted Answer

The long-term outlook for individuals with combined oxidative phosphorylation defect type 9 can vary widely. Some children may stabilize after an initial decline in development, while others may continue to face significant challenges, especially with cardiac and metabolic functions. With advancements in care and regular monitoring, many families are finding improved outcomes, but the prognosis can depend on the severity of symptoms and timely interventions.

Question 11

What specialists should families consult for combined oxidative phosphorylation defect type 9?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 9 should consult a team of specialists to provide comprehensive care. This may include a pediatrician, a geneticist for counseling, a cardiologist for heart issues, and a metabolic specialist to address metabolic concerns. Working with a multidisciplinary team helps ensure that all aspects of the condition are managed effectively, leading to better overall care.

Research Type	Count	% of Total
Laboratory research	12	67%

Kisho

combined oxidative phosphorylation defect type 9

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation defect type 9

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 9?

What are the symptoms of combined oxidative phosphorylation defect type 9?

What causes combined oxidative phosphorylation defect type 9?

How is combined oxidative phosphorylation defect type 9 inherited?

How rare is combined oxidative phosphorylation defect type 9?

How is combined oxidative phosphorylation defect type 9 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 9?

What complications can arise from combined oxidative phosphorylation defect type 9?

How does combined oxidative phosphorylation defect type 9 affect daily life for patients and families?

What is the long-term outlook for someone with combined oxidative phosphorylation defect type 9?

What specialists should families consult for combined oxidative phosphorylation defect type 9?

Explore clinical features

Recent Publications